The European LEMS Registry: Baseline Demographics and Treatment Approaches

Area of Science:

• Neurology
• Autoimmune Disorders
• Clinical Research

Background:

• Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder impacting the neuromuscular junction, causing muscle weakness and autonomic dysfunction.
• LEMS can be paraneoplastic (associated with cancer) or idiopathic (without cancer).
• Existing data on LEMS patient populations are limited despite available treatment guidelines.

Purpose of the Study:

• To establish a European registry for Lambert-Eaton myasthenic syndrome (LEMS) to gather comprehensive population data.
• To collect structured empirical data on the clinical course, treatment utilization, safety, and efficacy of LEMS-specific treatments.

Main Methods:

• A voluntary, multinational, observational, non-interventional LEMS patient registry was launched in the European community in mid-2010.
• The registry collects structured data on clinical assessments, laboratory findings, and treatment practices.

Main Results:

• Sixty-nine patients were enrolled, with 26% diagnosed with associated carcinoma.
• The majority of patients (65%) were receiving amifampridine (3,4-diaminopyridine) at enrollment.
• Patients presented with mild-to-moderate functional deficits, reduced reflexes, ataxia, and autonomic dysfunction (dry mouth, bladder issues, constipation).

Conclusions:

• The LEMS European Union registry will continue patient enrollment and periodic reporting of longitudinal data.
• The registry aims to provide insights into treatment practices, safety, efficacy, and long-term outcomes for LEMS patients.